Compare AbbVie Inc (ABBV) vs Zillow Group Inc Class A (ZG) Price & Performance

AbbVie (ABBV) trades at $248.40, up 0.2% with a bullish technical signal supported by moving averages. The company demonstrates strong revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity highlight ongoing momentum. Valuation ratios appear elevated with a P/E of 70.65 and P/B of 245.29, reflecting premium pricing for its pharmaceutical pipeline.

Outlook remains positive with 70.7% analyst buy ratings and a $278.69 consensus target offering 12% upside. Key risks include patent expirations, regulatory challenges from drug pricing lawsuits, and high debt levels. The dividend aristocrat status and robust immunology portfolio position ABBV for sustained growth, though investors should monitor execution against lofty 2026 EPS expectations of $3.87 for Q3.

Zillow Group (ZG) trades at $32.97, down 3.23% today, reflecting near-term pressure amid a securities class action deadline. The stock shows a bearish technical signal with support at $32 and resistance at $35. Fundamentally, revenue grew to $2.58B in 2025 with a net income of $23M, marking a return to profitability after losses in prior years, though valuation ratios like a P/E of 149 indicate high expectations. Recent Q2 2026 earnings beat expectations with 18% revenue growth, driven by the Preferred Agent model.

The outlook is mixed: analyst consensus is a Buy with a $47.56 price target, suggesting 44% upside, but risks include legal overhangs from the class action and a high P/E requiring sustained growth. Investors should weigh the bullish monetization shift against near-term volatility and profitability challenges.